The use of Laser Therapy (ILIB) in pain and improvement of quality of life of patients with Rheumatoid Arthritis

Analysis of the effectiveness of Laser Therapy (ILIB) for pain, kinesiophobia, handgrip strength and impact on the quality of life of patients with Rheumatoid Arthritis: planned and controlled clinical trial - ILIB Intravascular Laser Irradiation of Blood

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-93gmjsz

Enrollment

Unknown

Registered

2024-09-04

Start date

2024-09-15

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Rheumatoid

Interventions

This is a clinical, randomized and controlled study that will be carried out at the Physiotherapy Clinic of Centro de Saúde Nova Esperança - CSNE. The study will consist of 36 participants, between 35

E07.632.490

Eligibility

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: People with rheumatoid arthritis; aged between 35 and 75 years; both genders; with joint signs and symptoms lasting at least three months; able to fill out the Informed Consent Form

Exclusion criteria

Exclusion criteria: People with juvenile idiopathic arthritis; pregnancy; collagenous tissue diseases; chronic infectious disease; severe acute or chronic underlying disease; with changes in clotting factors; with hemorrhages; glaucoma; pregnant women; with a malignant tumor or cancer and missing more than 25% of irradiation treatment sessions

Design outcomes

Primary

Measure	Time frame
It is assumed that the results obtained with this study after applying the modified ILIB laser therapy protocol will present a significant improvement in pain;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in kinesiphobia;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in handgrip strength;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in quality of life;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in the performance of ADLs, improvements in work activities and social life	—

Measure

Time frame

It is assumed that the results obtained with this study after applying the modified ILIB laser therapy protocol will present a significant improvement in pain;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in kinesiphobia;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in handgrip strength;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in quality of life;It is assumed that the results obtained from this study after the application of the modified ILIB laser therapy protocol, presents a significant improvement in the performance of ADLs, improvements in work activities and social life

—

Secondary

Measure	Time frame
The results are expected to contribute to the production of new scientific evidence and it is intended, at the end of this study, to publish the data in existing journals and/or scientific events. In compliance with Resolution No. 466/2012 of the National Health Council, as well as by Operational Standard No. 001/2013MS/CNS (BRAZIL, 2013)	—

Countries

Brazil

Contacts

Public ContactSimoni Bittar

Universidade Federal da Paraíba

simonibittar@hotmail.com55(83)98182-9597

Outcome results

None listed

Source: REBEC (via WHO ICTRP)